Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection

About this Medicine

Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection contains two monoclonal antibodies used together for the emergency treatment of mild to moderate COVID-19 in adults and children aged 12 years and above and over 40 kg in weight. It is most effective if taken after an early laboratory diagnosis (within 7 to 10 days). This monoclonal antibody cocktail received emergency use approval from the Central Drug Standard Control Organization (CDSCO) on May 3rd, 2021. Apart from India, it has been approved for use in the United States, Switzerland, Germany, Italy, France, and several other countries.Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection should be given either into a vein (intravenously) or below the skin (subcutaneously) by a trained healthcare professional, preferably in a hospital setup. This is because the use of monoclonal antibodies may cause some side effects that may need immediate medical attention, such as severe allergic reactions (anaphylaxis). Patients should be monitored during and at least 1 hour after the injection.The most common side effects of this monoclonal antibody therapy are injection site reactions, fever, flushing, shortness of breath, chest tightness, nausea, and vomiting. If you experience any of these side effects, let your doctor know immediately.Before receiving this medicine, let your doctor know if you have any pre-existing medical conditions. Let the doctor know about your other medications if any, as they may affect or get affected by this COVID-19 drug. This medicine may be given to pregnant or breastfeeding women after considering its benefits against the risk to the baby or the mother.Contact UsIf you want to know about the medicine availability or need help to identify where you can get it administered, please fill in your details here and we will reach out to you.

How it Works

Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection is a combination of two human immunoglobulins G-1 (IgG1), neutralizing monoclonal antibodies, that bind at different sites on the spike protein of SARS-CoV-2, the virus that causes COVID-19. This unique binding mechanism, developed using recombinant DNA technology, is equally effective against the existing as well as newer emerging variants and prevents the virus from attaching to the human cell receptors.

Key Facts

Habit Forming :: No

Safety Overview